Axsome Therapeutics
AXSM
348 hedge funds and large institutions have $3.95B invested in Axsome Therapeutics in 2025 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 154 increasing their positions, 90 reducing their positions, and 57 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 90
0.09% more ownership
Funds ownership: 76.79% → 76.88% (+0.09%)
4% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 57
4% less call options, than puts
Call options by funds: $66.7M | Put options by funds: $69.3M
1% less funds holding
Funds holding: 353 → 348 (-5)
10% less capital invested
Capital invested by funds: $4.37B → $3.95B (-$417M)
42% less funds holding in top 10
Funds holding in top 10: 12 → 7 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$84.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$61.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$42.2M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$39.3M |
| 5 |
BlackRock
New York
|
+$32.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$149M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$47.3M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$42.4M |
| 4 |
D.E. Shaw & Co
New York
|
-$36.7M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$30.2M |
AXSM Hedge Fund Activity: Q2 2025 in Review
348 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2025, worth a combined $3.95B — down 9.5% from $4.37B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of AXSM and 55 opened new positions — a net loss of 2 holders — while 90 trimmed existing stakes and 154 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $84.9M. The largest seller was RTW Investments, cutting an estimated $149M.
- 348 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2025, down from 353 in Q1 2025.
- Funds reported $3.95B of Axsome Therapeutics stock for Q2 2025, down 9.5% quarter-over-quarter.
- 55 funds opened new Axsome Therapeutics positions in Q2 2025 and 57 closed out, a net change of -2 holders.
- The largest Axsome Therapeutics buyer in Q2 2025 was Deep Track Capital, an estimated $84.9M added.
- The largest Axsome Therapeutics seller in Q2 2025 was RTW Investments, an estimated $149M sold.
Based on aggregated 13F filings for Q2 2025.